Business
Gemini Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments
About this update from Disc Medicine, Inc.
[{"type":"text","content":" CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nGemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the following investor conferences in November:\n\nStifel 2021 Virtual Healthcare Conference\nDate: Monday, November 15, 2021\nTime: 8:40 AM ET\n\nJefferies London Healthcare Conference\nDate: Thursday, November 18, 2021\nThe presentation will be available on-demand starting at 8 AM GMT on Thursday, November 18, 2021.\n\nThe webcasts of the events will be available on the \"Events & Presentations\" page on the Company's website. A replay of the webcasts will be archived on the Company's website for 30 days following the presentations.\n\nAbout Gemini Therapeutics\n\nGemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD). Gemini’s lead candidate, GEM103, is a recombinant form of human complement factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. GEM103 is currently in a Phase 2a trial in dry AMD patients with a CFH risk variant and a Phase 1/2a study in patients with neovascular age-related macular degeneration with or at risk for macular atrophy. Gemini is also working to advance a potentiating antibody for CFH, GEM307, towards clinical development for treatment of systemic diseases.\n\nFor more information, visit www.geminitherapeutics.com.\n\nAvailability of Other Information About Gemini Therapeutics\n\nInvestors and others should note that we communicate with our investors and the public using our website (www.geminitherapeutics.com), the investor relations website (https://investors.geminitherapeutics.com/), and on social media (Twitter and LinkedIn), including but not limited to investor presentations and investor fact sheets, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Gemini posts on these channels and websites could be deemed to be material information. As a result, Gemini encourages investors, the media, an...